• Explore /
  • Poster
  • / ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.

ARTO trial (NCT03449719), a randomized phase II trial enrolling oligometastatic castration-resistant prostate cancer patients treated with first-line abiraterone acetate with or without stereotactic body radiation therapy: Preliminary results comprehensive of biochemical outcomes and circulating tumor cells analysis.

Abstract Video & Slides Poster

Authors

null

Giulio Francolini

University of Florence, Florence, Italy

Giulio Francolini , Pietro Garlatti , Mauro Loi , Beatrice Detti , Michele Aquilano , Andrea Allegra , Barbara Guerrieri , Viola Salvestrini , Pamela Pinzani , Chiara Bellini , Francesca Salvianti , Giulia Stocchi , Lucia Pia Ciccone , Giulia Salvatore , Mariangela Sottili , Vanessa Di Cataldo , Isacco Desideri , Monica Mangoni , Icro Meattini , Lorenzo Livi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03449719

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 118)

DOI

10.1200/JCO.2021.39.6_suppl.118

Abstract #

118

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Giulio Francolini

First Author: Giulio Francolini

First Author: Phuoc T. Tran

First Author: Isobel Porter